Compare Pinterest Inc (PINS) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Pinterest Inc vs Recursion Pharmaceuticals Inc — how do they compare? Pinterest Inc trades at $20.6 (market cap $11.63B), while Recursion Pharmaceuticals Inc trades at $4 (market cap $2.14B). The key difference: Pinterest Inc is far larger — about 5.4× Recursion Pharmaceuticals Inc's market cap, and Recursion Pharmaceuticals Inc is more actively traded (30,789,535 versus 12,792,940). Which is the better fit depends on your goals — on Pluang, investors hold Pinterest Inc for 85 Days and Recursion Pharmaceuticals Inc for 22 Days on average.
| PINS | RXRX | |
|---|---|---|
Market Cap | $11.63B | $2.14B |
Volume | 12,792,940 | 30,789,535 |
Sector | Media | Health |
52-Week High | $35.24 | $6.79 |
52-Week Low | $15.42 | $2.84 |
Typical Hold Time | 85 Days | 22 Days |
Enterprise Value | $11.55B | $1.66B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Pinterest (PINS) trades at $20.31, up 1.4% today, with a bullish technical signal and strong earnings beats in recent quarters. Revenue growth accelerated to $4.22 billion in 2025, with a net income margin of 9.87%, while analyst consensus is a Buy with a $27.93 price target. Recent news highlights its undervaluation and new Visual Search Ads launch, though insider selling and cash flow volatility present mixed signals.
The outlook is positive given robust fundamentals and growth potential, but risks include competitive pressures and reliance on ad revenue. Upside is supported by earnings momentum and international monetization, yet investors should monitor cash flow trends and market sentiment shifts for sustained gains.
RXRX trades at $4.27, down 7.78% today, with technical indicators showing a bullish trend despite recent weakness. The company reported Q2 2026 earnings miss after two consecutive beats, with revenue declining to $54 million in 2026 from $74 million in 2025. While maintaining a negative net income margin of -961.97%, RXRX continues to expand its AI-powered drug discovery platform through strategic partnerships with Tempus and Roche.
The stock presents high-risk growth potential with strong analyst support (40% buy rating) but faces significant execution challenges. Investment appeal hinges on successful pipeline development and commercialization of AI drug discovery technology, though persistent losses and declining revenue create substantial downside risk for shareholders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Pinterest Inc
Pinterest is an online product and idea discovery platform that helps users gather ideas on everything from recipes to cook to destinations to travel to. Founded in 2010, the platform consists of a largely female audience, at roughly two thirds of its more than 365 million monthly active users. The company generates revenue by selling digital ads and is now rolling out more in-platform e-commerce features.
Read more on PINS →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
